The global inhalation CDMO industry is expected to expand at a CAGR of 5.7% in the forecast period 2024 to 2034. The market value is projected to increase from US$ 8,639.1 million in 2024 to US$ 14,863.6 million in 2034.
| Attributes | Key Insights |
|---|---|
| Base Value, 2023 | US$ 8,144.2 million |
| Estimated Global Inhalation CDMO Market Size (2024E) | US$ 8,639.1 million |
| Forecast Inhalation CDMO Market Value (2034F) | US$ 14,863.6 million |
| Value-based CAGR (2024 to 2034) | 5.7% |
The pharmaceutical landscape is undergoing a transformative phase marked by continual innovations in inhalation drug delivery systems, constituting a pivotal driver for the contract development and manufacturing organization (CDMO) market. This evolution encompasses a spectrum of advanced technologies, emphasizing dry powder inhalers (DPIs), metered-dose inhalers (MDIs), and nebulizers.
As respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD) become increasingly prevalent, the demand for efficacious and patient-friendly inhalation therapies escalates. Consequently, pharmaceutical companies are propelled to seek the expertise of specialized CDMOs to navigate the intricacies of these evolving delivery systems.
Formulation development, analytical testing, process optimization, and the production of inhalable medicinal products are the services provided by inhalation CDMOs. They could also help patients navigate the legal and regulatory procedures for developing respiratory drugs.
The expansion of the inhalation CDMO market is facilitated by advancements in inhalation technology, including the creation of unique medication formulations and inventive inhaler devices. Companies in this industry constantly invest in research & development to be on the cutting edge of technological advancements.
The inhalation CDMO market is expanding internationally, with firms offering their services to customers in several geographical areas. Pharmaceutical firms and inhalation CDMOs are increasingly forming partnerships and collaborations to pool resources and expertise.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global inhalation CDMO market recorded a historical CAGR of 4.0% from 2019 to 2023. The increasing prevalence of asthma and COPD drives the incidence of associated respiratory diseases.
In recent years, this has led to a surging demand for efficient respiratory care, including using respiratory inhaler devices. Healthcare professionals are increasingly inclined to adopt inhaler devices to deliver drugs directly to patients' respiratory tracts to ensure minimal wastage of drugs and to increase their efficacy.
The inhalation CDMO market experienced a notable impact from the escalating prevalence of asthma and chronic obstructive pulmonary disease (COPD). The rising incidence of these respiratory conditions has propelled the demand for inhaler devices, becoming a central driver in shaping the market dynamics.
The increasing prevalence of asthma and COPD has led to a growing patient population requiring long-term management and treatment. As a result, there is a heightened need for effective and convenient drug delivery systems, with inhaler devices emerging as a cornerstone in the therapeutic arsenal for these respiratory disorders.
The adoption of newly launched nebulizers with quick drug delivery inhalers would aid demand. In addition, a top-end technological assessment with greater accuracy is gaining traction among the population, further spurring revenue growth for the market.
The relentless pace of technological advancement is a driving force fueling the demand for respiratory inhaler devices and shaping the landscape of the respiratory healthcare market. Technical assessment plays a pivotal role in enhancing the capabilities and functionalities of inhaler devices.
The symbiotic relationship between technology and respiratory care drives the market toward innovative solutions. These would help offer improved patient outcomes, increased treatment adherence, and enhanced disease management.
Principal Consultant
The table below shows the estimated growth rates of the top five countries. China, Japan, and Spain are set to record higher CAGRs of 10.8%, 4.9%, and 3.8%, respectively, through 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| United States | 2.6% |
| China | 10.8% |
| Japan | 4.9% |
| Germany | 2.3% |
| Spain | 3.8% |
The United States dominated the global market and held a 33.1% market share in 2023. The United States is expected to exhibit a CAGR of 2.6% throughout the forecast period, driven by factors like:
The high prevalence of respiratory disorders such as asthma and COPD in the United States is a significant driver for the inhalation CDMO market. The demand for innovative inhalation therapies is surging, ultimately driving the growth of CDMOs in the United States.
In 2023, China held a dominant share of 7.7% in East Asia’s market. The market is expected to surge with a CAGR of 10.8% from 2024 to 2034. Some of the key drivers/trends include:
China faces a rising prevalence of respiratory disorders, including air pollution-related issues and an increasing number of smokers. This creates a substantial demand for advanced inhalation therapies, presenting an opportunity for CDMOs to cater to the growing healthcare needs in China.
China's pharmaceutical market is rapidly expanding, driven by a rising aging population, increased healthcare awareness, and high disposable income. This growth creates opportunities for CDMOs to collaborate with local and international pharmaceutical companies seeking inhalation drug development services.
Germany is expected to surge at a CAGR of 2.3% during the forecast period. This can be attributed to factors like:
Germany is a pharmaceutical hub with a strong emphasis on research and development activities. The country's well-established pharmaceutical industry demands specialized CDMOs, particularly those offering inhalation drug development expertise.
Germany's central location in Europe is a strategic base for companies that serve Europe’s pharmaceutical market. Inhalation CDMOs can leverage this location to establish a presence and cater to the diverse needs of the pharmaceutical industry.
Japan is set to surge at a CAGR of 4.9% between 2024 and 2034. Factors driving the market growth include:
In Japan, there is a high frequency of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD), which drives up demand for inhalation treatments. As a result, inhalation CDMOs now have the chance to work with pharmaceutical firms to develop and produce respiratory medicinal products.
Japan has a solid pharmaceutical regulation system in place. Operating in Japan, inhalation CDMOs must navigate and abide by the rules established by the Pharmaceuticals and Medical Devices Agency (PMDA). Comprehending and obeying these rules is essential to developing and effectively launching new products in the market.
Japan is renowned for its technological breakthroughs. The country’s inventive research and development in inhalation medication delivery methods and technologies can benefit inhalation CDMOs operating nationwide. Being at the forefront of these developments enables companies to provide their clients with state-of-the-art solutions.
Over the forecast period, demand for inhalation CDMO in Spain is expected to rise at a CAGR of 3.8%. This growth projection can be attributed to several key factors:
Spain is a vital country in the global pharmaceuticals market. Spain-based inhalation CDMOs can expand their offerings to serve clients abroad or collaborate with multinational pharmaceutical firms. Incorporating this integration with the global market can yield supplementary growth prospects.
The aging population of Spain is driving up demand for healthcare services and pushing the inhalation CDMO market. The elderly are more likely to suffer from respiratory disorders, which makes effective inhalation therapy necessary. By creating specialized respiratory therapies, inhalation CDMOs can help satisfy these healthcare demands.
For inhalation CDMOs, it is crucial to consider Spain’s market trends and cultural preferences. Inhalable medicine products can succeed more in Spain’s market if their formulations and delivery methods are customized to suit regional tastes and medical standards.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The below section shows the commercial segment dominating by scale of operation. It is expected to surge at a CAGR of 6.3% by 2034. Based on product, the API segment is anticipated to rise at a 6.0% CAGR by 2034.
| Segment | Value CAGR (2024 to 2034) |
|---|---|
| Commercial (Scale of Operation) | 6.3% |
| Formulation Development (Services) | 4.5% |
| API (Product) | 6.0% |
| Medium (Company Size) | 3.6% |
Collaborations and acquisitions are common growth strategies that leading companies employ in the inhalation CDMO market. They aim to enhance their capabilities, expand their service offerings, and stay competitive in the dynamic landscape.
For instance
| Attribute | Details |
|---|---|
| Estimated Market Size (2024) | US$ 8,639.1 million |
| Forecast Market Value (2034) | US$ 14,863.6 million |
| Anticipated Growth Rate (2024 to 2034) | 5.7% |
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | US$ million for Value |
| Key Regions Covered | North America; Latin America; East Asia; South Asia and Pacific; Western Europe; Eastern Europe; Middle East and Africa |
| Key Countries Covered | United States, Canada, Mexico, Brazil, Chile, China, Japan, South Korea, Germany, France, Spain, Italy, BENELUX, Nordic Countries, United Kingdom, BENELUX, Poland, Hungary, Romania, India, ASEAN Countries, Australia and New Zealand, GCC Countries, South Africa, and Türkiye |
| Key Market Segments Covered | Service, Product, Company Size, Scale of Operation, and Region |
| Key Companies Profiled | Recipharm AB; AptarGroup, Inc.; Hovione; Vectura Group Ltd; Nemera; Kindeva; H&T Presspart; Sanner GmbH; Stevanato Group; Medspray; ICONOVO AB; Lonza; Gerresheimer AG; Catalent; Patheon N.V. (Thermo Fisher Scientific, Inc.); Lubrizol Life Science; Enteris BioPharma; Cambrex Corporation; INKE; Piramal Pharma Limited; Lupin |
| Report Coverage | Market Forecast, Competition Intelligence, Drivers, Restraints, Opportunities, Trends Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
The global market was valued at US$ 8,144.2 million in 2023.
The market is set to reach a valuation of US$ 14,863.6 million by 2034.
Demand for inhalation CDMO increased at a 5.7% CAGR from 2019 to 2023.
The global market is projected to reach US$ 8,639.1 million by 2024.
The United States accounted for a 33.1% share of the global market in 2023.
Germany held around 2.3% market share in 2023.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Development/Innovation Trends
4. Value-Added Insights
4.1. Service Adoption / Usage Analysis, By
4.2. Disease Epidemiology, By Key Countries
4.3. Regulatory Scenario
4.3.1. Regulatory Frameworks in United States
4.3.2. Regulatory Frameworks in Canada
4.3.3. Regulatory Frameworks in Europe
4.3.4. Regulatory Frameworks in China
4.3.5. Regulatory Frameworks in Japan
4.3.6. Regulatory Frameworks in India
4.4. Overview of CRO and CDMO Services
4.5. Role of Contract Service Providers
4.6. Overview of CDMO with a Wide Array of Dosage Form Capabilities
4.7. PESTLE Analysis
4.8. Pharma Services Supply Chain Analysis
4.9. Value Chain Analysis
4.10. Sustainability Analysis and its Implications on Propellant Market Dynamics
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global Healthcare Expenditure
5.1.2. R&D Funding Outlook, By Region
5.1.3. R&D Funding Outlook, By Country
5.1.4. Global API CDMO Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Growing Prevalence of Respiratory Diseases
5.2.2. Advancements in Inhalation Technology
5.2.3. Increasing Focus on Personalized Medicine
5.2.4. Rising Demand for Generic and Biosimilar Inhalation Products
5.2.5. Regulatory Changes and Compliance Requirements
5.2.6. Increasing Outsourcing of Inhalation Product Development
5.2.7. Globalization of Pharmaceutical Supply Chains
5.2.8. Emerging Markets and Untapped Opportunities
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand (in Value or Size in US$ million) Analysis 2019 to 2023 and Forecast, 2024 to 2034
6.1. Historical Market Value (US$ million) Analysis, 2019 to 2023
6.2. Current and Future Market Value (US$ million) Projections, 2024 to 2034
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Services
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ million) Analysis By Services, 2019 to 2023
7.3. Current and Future Market Size (US$ million) Analysis and Forecast By Services, 2024 to 2034
7.3.1. Formulation Development
7.3.2. Device Development and Manufacturing
7.3.3. Clinical Manufacturing
7.3.4. Scale-up and Tech Transfer
7.3.5. Quality Control and Quality Assurance
7.3.6. Technology and Innovation
7.3.7. Regulatory Assistance
7.3.8. Analytical Services
7.4. Market Attractiveness Analysis By Services
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ million) By Product, 2019 to 2023
8.3. Current and Future Market Size (US$ million) Analysis and Forecast By Product, 2024 to 2034
8.3.1. API
8.3.1.1. API Substrate
8.3.1.2. Large Molecule
8.3.1.3. Small Molecule
8.3.2. Inhalation Platform
8.3.2.1. Dry Powder Inhalers (DPIs)
8.3.2.2. Metered Dose Inhalers (MDIs)
8.3.2.3. Soft Mist Inhaler
8.4. Market Attractiveness Analysis By Product
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Company Size
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ million) By Company Size, 2019 to 2023
9.3. Current and Future Market Size (US$ million) Analysis and Forecast By Company Size, 2024 to 2034
9.3.1. Large
9.3.2. Medium
9.3.3. Small
9.4. Market Attractiveness Analysis By Company Size
10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Scale of Operation
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ million) By Scale of Operation, 2019 to 2023
10.3. Current and Future Market Size (US$ million) Analysis and Forecast By Scale of Operation, 2024 to 2034
10.3.1. Preclinical
10.3.2. Clinical
10.3.3. Commercial
10.4. Market Attractiveness Analysis By Scale of Operation
11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ million) Trend Analysis by Region, 2019 to 2023
11.3. Current and Future Market Size (US$ million) Analysis and Forecast by Region, 2024 to 2034
11.3.1. North America
11.3.2. Latin America
11.3.3. East Asia
11.3.4. South Asia & Pacific
11.3.5. Western Europe
11.3.6. Eastern Europe
11.3.7. Middle East and Africa
11.4. Market Attractiveness Analysis by Region
12. North America Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034
12.1. Introduction
12.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023
12.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
12.3.1. By Country
12.3.1.1. United States
12.3.1.2. Canada
12.3.2. By Services
12.3.3. By Product
12.3.4. By Company Size
12.3.5. By Scale of Operation
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Services
12.4.3. By Product
12.4.4. By Company Size
12.4.5. By Scale of Operation
12.5. Market Trends
12.6. Drivers & Restraints Impact Analysis
12.7. Country-Wise Analysis
12.7.1. United States Market Analysis
12.7.1.1. Introduction
12.7.1.2. Market Analysis and Forecast by Market Taxonomy
12.7.1.2.1. By Services
12.7.1.2.2. By Product
12.7.1.2.3. By Company Size
12.7.1.2.4. By Scale of Operation
12.7.2. Canada Market Analysis
12.7.2.1. Introduction
12.7.2.2. Market Analysis and Forecast by Market Taxonomy
12.7.2.2.1. By Services
12.7.2.2.2. By Product
12.7.2.2.3. By Company Size
12.7.2.2.4. By Scale of Operation
12.7.3. Mexico Market Analysis
12.7.3.1. Introduction
12.7.3.2. Market Analysis and Forecast by Market Taxonomy
12.7.3.2.1. By Services
12.7.3.2.2. By Product
12.7.3.2.3. By Company Size
12.7.3.2.4. By Scale of Operation
13. Latin America Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034
13.1. Introduction
13.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023
13.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
13.3.1. By Country
13.3.1.1. Brazil
13.3.1.2. Chile
13.3.1.3. Rest of Latin America
13.3.2. By Services
13.3.3. By Product
13.3.4. By Company Size
13.3.5. By Scale of Operation
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Services
13.4.3. By Product
13.4.4. By Company Size
13.4.5. By Scale of Operation
13.5. Market Trends
13.6. Drivers & Restraints Impact Analysis
13.7. Country-Wise Analysis
13.7.1. Brazil Market Analysis
13.7.1.1. Introduction
13.7.1.2. Market Analysis and Forecast by Market Taxonomy
13.7.1.2.1. By Services
13.7.1.2.2. By Product
13.7.1.2.3. By Company Size
13.7.1.2.4. By Scale of Operation
13.7.2. Chile Market Analysis
13.7.2.1. Introduction
13.7.2.2. Market Analysis and Forecast by Market Taxonomy
13.7.2.2.1. By Services
13.7.2.2.2. By Product
13.7.2.2.3. By Company Size
13.7.2.2.4. By Scale of Operation
14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034
14.1. Introduction
14.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023
14.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
14.3.1. By Country
14.3.1.1. China
14.3.1.2. Japan
14.3.1.3. South Korea
14.3.2. By Services
14.3.3. By Product
14.3.4. By Company Size
14.3.5. By Scale of Operation
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Services
14.4.3. By Product
14.4.4. By Company Size
14.4.5. By Scale of Operation
14.5. Market Trends
14.6. Drivers & Restraints Impact Analysis
14.7. Country-Wise Analysis
14.7.1. China Market Analysis
14.7.1.1. Introduction
14.7.1.2. Market Analysis and Forecast by Market Taxonomy
14.7.1.2.1. By Services
14.7.1.2.2. By Product
14.7.1.2.3. By Company Size
14.7.1.2.4. By Scale of Operation
14.7.2. Japan Market Analysis
14.7.2.1. Introduction
14.7.2.2. Market Analysis and Forecast by Market Taxonomy
14.7.2.2.1. By Services
14.7.2.2.2. By Product
14.7.2.2.3. By Company Size
14.7.2.2.4. By Scale of Operation
14.7.3. South Korea Market Analysis
14.7.3.1. Introduction
14.7.3.2. Market Analysis and Forecast by Market Taxonomy
14.7.3.2.1. By Services
14.7.3.2.2. By Product
14.7.3.2.3. By Company Size
14.7.3.2.4. By Scale of Operation
15. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034
15.1. Introduction
15.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023
15.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
15.3.1. By Country
15.3.1.1. India
15.3.1.2. ASEAN Countries
15.3.1.3. Australia & New Zealand
15.3.1.4. Rest of South Asia
15.3.2. By Services
15.3.3. By Product
15.3.4. By Company Size
15.3.5. By Scale of Operation
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Services
15.4.3. By Product
15.4.4. By Company Size
15.4.5. By Scale of Operation
15.5. Market Trends
15.6. Drivers & Restraints Impact Analysis
15.7. Country-Wise Analysis
15.7.1. India Market Analysis
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast by Market Taxonomy
15.7.1.2.1. By Services
15.7.1.2.2. By Product
15.7.1.2.3. By Company Size
15.7.1.2.4. By Scale of Operation
15.7.2. ASEAN Countries Market Analysis
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast by Market Taxonomy
15.7.2.2.1. By Services
15.7.2.2.2. By Product
15.7.2.2.3. By Company Size
15.7.2.2.4. By Scale of Operation
15.7.3. Australia & New Zealand Market Analysis
15.7.3.1. Introduction
15.7.3.2. Market Analysis and Forecast by Market Taxonomy
15.7.3.2.1. By Services
15.7.3.2.2. By Product
15.7.3.2.3. By Company Size
15.7.3.2.4. By Scale of Operation
16. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034
16.1. Introduction
16.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023
16.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
16.3.1. By Country
16.3.1.1. Germany
16.3.1.2. France
16.3.1.3. Spain
16.3.1.4. Italy
16.3.1.5. BENELUX
16.3.1.6. Nordic Countries
16.3.1.7. United Kingdom
16.3.1.8. Rest of Western Europe
16.3.2. By Services
16.3.3. By Product
16.3.4. By Company Size
16.3.5. By Scale of Operation
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Services
16.4.3. By Product
16.4.4. By Company Size
16.4.5. By Scale of Operation
16.5. Market Trends
16.6. Drivers & Restraints Impact Analysis
16.7. Country-Wise Analysis
16.7.1. Germany Market Analysis
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast by Market Taxonomy
16.7.1.2.1. By Services
16.7.1.2.2. By Product
16.7.1.2.3. By Company Size
16.7.1.2.4. By Scale of Operation
16.7.2. France Market Analysis
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast by Market Taxonomy
16.7.2.2.1. By Services
16.7.2.2.2. By Product
16.7.2.2.3. By Company Size
16.7.2.2.4. By Scale of Operation
16.7.3. Spain Market Analysis
16.7.3.1. Introduction
16.7.3.2. Market Analysis and Forecast by Market Taxonomy
16.7.3.2.1. By Services
16.7.3.2.2. By Product
16.7.3.2.3. By Company Size
16.7.3.2.4. By Scale of Operation
16.7.4. Italy Republic Market Analysis
16.7.4.1. Introduction
16.7.4.2. Market Analysis and Forecast by Market Taxonomy
16.7.4.2.1. By Services
16.7.4.2.2. By Product
16.7.4.2.3. By Company Size
16.7.4.2.4. By Scale of Operation
16.7.5. BENELUX Republic Market Analysis
16.7.5.1. Introduction
16.7.5.2. Market Analysis and Forecast by Market Taxonomy
16.7.5.2.1. By Services
16.7.5.2.2. By Product
16.7.5.2.3. By Company Size
16.7.5.2.4. By Scale of Operation
16.7.6. Nordic Countries Market Analysis
16.7.6.1. Introduction
16.7.6.2. Market Analysis and Forecast by Market Taxonomy
16.7.6.2.1. By Services
16.7.6.2.2. By Product
16.7.6.2.3. By Company Size
16.7.6.2.4. By Scale of Operation
16.7.7. United Kingdom Market Analysis
16.7.7.1. Introduction
16.7.7.2. Market Analysis and Forecast by Market Taxonomy
16.7.7.2.1. By Services
16.7.7.2.2. By Product
16.7.7.2.3. By Company Size
16.7.7.2.4. By Scale of Operation
17. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034
17.1. Introduction
17.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023
17.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
17.3.1. By Country
17.3.1.1. Poland
17.3.1.2. Hungary
17.3.1.3. Russia
17.3.1.4. Rest of Eastern Europe
17.3.2. By Services
17.3.3. By Product
17.3.4. By Company Size
17.3.5. By Scale of Operation
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Services
17.4.3. By Product
17.4.4. By Company Size
17.4.5. By Scale of Operation
17.5. Market Trends
17.6. Drivers & Restraints Impact Analysis
17.7. Country-Wise Analysis
17.7.1. Poland Market Analysis
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast by Market Taxonomy
17.7.1.2.1. By Services
17.7.1.2.2. By Product
17.7.1.2.3. By Company Size
17.7.1.2.4. By Scale of Operation
17.7.2. Hungary Market Analysis
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast by Market Taxonomy
17.7.2.2.1. By Services
17.7.2.2.2. By Product
17.7.2.2.3. By Company Size
17.7.2.2.4. By Scale of Operation
17.7.3. Russia Market Analysis
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast by Market Taxonomy
17.7.3.2.1. By Services
17.7.3.2.2. By Product
17.7.3.2.3. By Company Size
17.7.3.2.4. By Scale of Operation
18. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034
18.1. Introduction
18.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023
18.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
18.3.1. By Country
18.3.1.1. Saudi Arabia
18.3.1.2. Türkiye
18.3.1.3. South Africa
18.3.1.4. Other African Union
18.3.1.5. Rest of Middle East and Africa
18.3.2. By Services
18.3.3. By Product
18.3.4. By Company Size
18.3.5. By Scale of Operation
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Services
18.4.3. By Product
18.4.4. By Company Size
18.4.5. By Scale of Operation
18.5. Market Trends
18.6. Drivers & Restraints Impact Analysis
18.7. Country-Wise Analysis
18.7.1. Saudi Arabia Market Analysis
18.7.1.1. Introduction
18.7.1.2. Market Analysis and Forecast by Market Taxonomy
18.7.1.2.1. By Services
18.7.1.2.2. By Product
18.7.1.2.3. By Company Size
18.7.1.2.4. By Scale of Operation
18.7.2. Türkiye Market Analysis
18.7.2.1. Introduction
18.7.2.2. Market Analysis and Forecast by Market Taxonomy
18.7.2.2.1. By Services
18.7.2.2.2. By Product
18.7.2.2.3. By Company Size
18.7.2.2.4. By Scale of Operation
18.7.3. South Africa Market Analysis
18.7.3.1. Introduction
18.7.3.2. Market Analysis and Forecast by Market Taxonomy
18.7.3.2.1. By Services
18.7.3.2.2. By Product
18.7.3.2.3. By Company Size
18.7.3.2.4. By Scale of Operation
18.7.4. Other African Union Market Analysis
18.7.4.1. Introduction
18.7.4.2. Market Analysis and Forecast by Market Taxonomy
18.7.4.2.1. By Services
18.7.4.2.2. By Product
18.7.4.2.3. By Inhalation Platform
19. Competition Analysis
19.1. Competition Dashboard
19.2. Top Devices CDMO’s Market Positioning
19.2.1. Current Market Scenario (2024)
19.2.2. Short Term Forecast (2025)
19.2.3. Long Tem Forecast (2034)
19.3. Market Share Assessment
19.4. CDMO Market Insights
19.5. Competition Deep Dive
19.5.1. Recipharm AB
19.5.1.1. Overview
19.5.1.2. Inhalation Platform Portfolio
19.5.1.3. Key Financials
19.5.1.4. SWOT Analysis
19.5.1.5. Key Developments
19.5.1.6. Sales Footprint
19.5.1.7. Strategy Overview
19.5.1.7.1. Marketing Strategy
19.5.1.7.2. Inhalation Platform Strategy
19.5.1.7.3. Channel Strategy
19.5.2. AptarGroup, Inc.
19.5.3. Hovione
19.5.4. Vectura Group Ltd.
19.5.5. Nemera
19.5.6. Kindeva
19.5.7. H&T Presspart
19.5.8. Sanner GmbH
19.5.9. Stevanato Group
19.5.10. Medspray
19.5.11. ICONOVO AB
19.5.12. Lonza
19.5.13. Gerresheimer AG
19.5.14. Catalent
19.5.15. Patheon N.V. (Thermo Fisher Scientific, Inc.)
19.5.16. Lubrizol Life Science
19.5.17. Enteris BioPharma
19.5.18. Cambrex Corporation
19.5.19. INKE
19.5.20. Piramal Pharma Limited
19.5.21. Lupin
20. Assumptions and Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Inhalation CDMO Market
